[HTML][HTML] Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations
J Remon, F Passiglia, MJ Ahn, F Barlesi… - Journal of Thoracic …, 2020 - Elsevier
In the past 10 years, a deeper understanding of the immune landscape of cancers, including
immune evasion processes, has allowed the development of a new class of agents. The …
immune evasion processes, has allowed the development of a new class of agents. The …
[HTML][HTML] European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment-update 2022
A unique collaboration of multidisciplinary experts from the European Dermatology Forum
(EDF), the European Association of Dermato-Oncology (EADO), and the European …
(EDF), the European Association of Dermato-Oncology (EADO), and the European …
Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology
DG Coit, JA Thompson, MR Albertini, C Barker… - Journal of the National …, 2019 - jnccn.org
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous
melanoma have been significantly revised over the past few years in response to emerging …
melanoma have been significantly revised over the past few years in response to emerging …
[HTML][HTML] European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment–update 2019
A unique collaboration of multidisciplinary experts from the European Dermatology Forum,
the European Association of Dermato-Oncology and the European Organization for …
the European Association of Dermato-Oncology and the European Organization for …
Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915)
JS Weber, D Schadendorf, M Del Vecchio… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Ipilimumab and nivolumab have each shown treatment benefit for high-risk
resected melanoma. The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus …
resected melanoma. The phase III CheckMate 915 trial evaluated adjuvant nivolumab plus …
[HTML][HTML] A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
Background Pembrolizumab is approved for multiple cancer types at 200 mg and 2 mg/kg
dose every 3 weeks (Q3W). We used a model-based approach to compare the exposure of …
dose every 3 weeks (Q3W). We used a model-based approach to compare the exposure of …
Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update
PURPOSE To provide recommendations for appropriate dosing of systemic antineoplastic
agents in obese adults with cancer. METHODS A systematic review of the literature collected …
agents in obese adults with cancer. METHODS A systematic review of the literature collected …
[HTML][HTML] ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer
The COVID-19 pandemic, characterised by a fast and global spread during the first months
of 2020, has prompted the development of a structured set of recommendations for cancer …
of 2020, has prompted the development of a structured set of recommendations for cancer …
PD-1/PD-L1 inhibitors in cervical cancer
Y Liu, L Wu, R Tong, F Yang, L Yin, M Li… - Frontiers in …, 2019 - frontiersin.org
Cervical cancer is one of the most common gynecological tumors, and the majority of early-
stage cervical cancer patients achieve good recovery through surgical treatment and …
stage cervical cancer patients achieve good recovery through surgical treatment and …
Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy
Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1 or CD279)
have noticeably improved the treatment landscape of advanced cancer patients. Nivolumab …
have noticeably improved the treatment landscape of advanced cancer patients. Nivolumab …